EDSA Edesa Biotech, Inc.

$5.35

Edesa Biotech, Inc. (EDSA) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $0.44 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -6.0% since its last earnings release on August 13, 2026.

Edesa Biotech Missed Consensus Estimates
Thursday, August 13, 2026 · 4:15 PM ET
Earnings Date
4th Quarter, Sep 2026
Nov 12
Thursday · 4:30 PM ET
Earnings Whisper
-
vs ($0.44)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $5.35

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Edesa Biotech, Inc.

Edesa Biotech Inc. is a biopharmaceutical company. It is focused on acquiring, developing and commercializing clinical stage drugs for dermatological and gastrointestinal indications with clear unmet medical needs. The company's product pipeline consists of EB01, EB02 and EB04 which are in clinical stage. Edesa Biotech Inc., formerly known as Stellar Biotechnologies Inc., is based in TORONTO.

Sector

Healthcare

Industry

Biotechnology